Search PubMed⌕ Search

Biomedical subjects

D J Munjack

Publications and source records attributed to D J Munjack.

25 records · Page 2Linked to original sources
PubMed1979

Sex and drugs.

Explore the source record for details and available documents.

Central Nervous System Depressants↗
PubMed1978

Resistance in the behavioral treatment of sexual dysfunctions.

Although there has been a rapid burgeoning of interest in the treatment of sexual problems in recent years, particularly in treatments that include or rely heavily upon learning-based behavioral intervention strategies, little has been written about the patient "resistances" during this form of treatment. This report describes five categories of resistance: Type I resistance results from the patient not understanding what he is supposed to do, Type II resistance from a deficit in the patient's skills, Type III resistance from lack of motivation or expectation of success, Type IV resistance from anxiety or gulit elicited or mobilized by the treatment situation, and Type V resistance from positive reinforcement (secondary gain). Treatment strategies differ depending on the type of resistance.

Anxiety↗
PubMed1976

Psychological characteristics of women with sexual inhibition (frigidity) in six clinics.

Traditional psychiatric thought has equated the inability of a female to obtain an orgasm (particularly a vaginal orgasm during intercourse) with psychological maladjustment. The research literature generally does not support this position. The present paper describes the psychological characteristics of 44 frigid women who applied for treatment of their sexual problem at two university hospital sex clinics and 26 women selected for treatment by the same criterion, but treated in private practice. Presented for comparison are 53 female neurotics from a Temple University Hospital psychotherapy study, a sample of 65 consecutive female walk-ins of mixed psychiatric diagnosis from the Psychiatric Outpatient Clinic of Temple Hospital, and a group of 35 female college student sophomores from Temple University who comprised the normal sample. A battery of psychological tests including the MMPI, the Institute for Personality and Ability Testing--Self-Evaluation Form (IPAT), the Symptom Check List, and the Eysenck Personality Inventory were given to each group. The data indicate that female patients who apply to a sex dysfunction clinic, complaining primarily of sexual inhibition, appear as a group identical to a normal control group in terms of their psychological profile and less neurotic than psychiatric outpatients, with the exception that the normals were less depressed. When women with primary orgasmic dysfunction from the above three samples were combined and compared to those with secondary orgasmic dysfunction (using Masters and Johnson's criterion), the groups were identical, at least from a global psychological perspective. We suggest that little else can be gained by assessing global personality characteristics. Without discarding the primary and secondary classifications a potentially more fruitful approach would be to develop instruments that would measure specific dimensions, such as sexual misinformation, specific sexual anxiety or guilt, or resentment or hostility directed toward the immediate sexual partner. A scale to measure specific phobic-like sexual anxiety, in addition, would have treatment implications because of the recently demonstrated effectiveness of specific anxiety-reducing techniques, such as systematic desensitization. Specific scales can also be useful in the assessment and prediction of outcome in psychotherapy.

Adolescent↗
PubMedDate not supplied

Sertraline in social phobia.

Eleven consecutive SCID-diagnosed generalized social phobias without major depression, other prominent anxiety disorders, substance abuse, alcoholism or organic mental disorder, were treated, open label, with sertraline up to 200 mg daily for 12 weeks. There were seven completers. Of these, five showed substantial improvement, after being on sertraline 100 mg daily for two weeks (following no response to sertraline 50 mg daily for four weeks). There were few side effects among the completers. The four dropouts complained of side effects and loss of interest in continuing treatment. Final average dose for completers who responded was 170 mg daily.

1-Naphthylamine↗